The ruling blocks Lupin and Zydus Life from selling their generic version of Mirabegron, the bioequivalent of Astellas' ...

The litigation was initiated by Astellas Pharma against Zydus Lifesciences concerning the validity of the ‘780 patent’, which ...

Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40 ...

Easy Trip Planners Ltd, Dhani Services Ltd, Mahanagar Gas Ltd and Astrazeneca Pharma India Ltd are among the other losers in the BSE's 'A' group today, 16 April 2025.

Lupin Ltd. and Zydus Lifesciences Ltd. shares fell sharply after a US court upheld Astellas Pharma's patent on Myrbetriq, ...

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

The GIFT Nifty was indicating a muted start for Indian benchmarks on Tuesday. ICICI Bank Ltd., HCLTech Ltd., and Zydus Lifesciences Ltd. share prices are expected to move because of the news flow over ...

Stocks including HCL Technologies, IRCON International, Zydus Lifesciences, Tata Power, Cyient, Indian Hotels, JK Cement, Havells and Macrotech Developers will be in the spotlight on Tuesday, April 15 ...

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.

Explore the latest stock alerts: Macrotech, Reliance, Vedanta, Dr Reddy's, and more. Check out key developments today!